Systemic IL-27 administration prevents abscess formation and osteolysis via local neutrophil recruitment and activation

Abstract

Interleukin-27 is a pleiotropic cytokine whose functions during bacterial infections remain controversial, and its role in patients with S. aureus osteomyelitis is unknown. To address this knowledge gap, we completed a clinical study and observed elevated serum IL-27 levels (20-fold higher, P < 0.05) in patients compared with healthy controls. Remarkably, IL-27 serum levels were 60-fold higher in patients immediately following septic death than in uninfected patients (P < 0.05), suggesting a pathogenic role of IL-27. To test this hypothesis, we evaluated S. aureus osteomyelitis in WT and IL-27Rα^−/− mice with and without exogenous IL-27 induction by intramuscular injection of rAAV-IL-27p28 or rAAV-GFP, respectively. We found that IL-27 was induced at the surgical site within 1 day of S. aureus infection of bone and was expressed by M0, M1 and M2 macrophages and osteoblasts but not by osteoclasts. Unexpectedly, exogenous IL-27p28 (~2 ng·mL⁻¹ in serum) delivery ameliorated soft tissue abscesses and peri-implant bone loss during infection, accompanied by enhanced local IL-27 expression, significant accumulation of RORγt⁺ neutrophils at the infection site, a decrease in RANK⁺ cells, and compromised osteoclast formation. These effects were not observed in IL-27Rα^−/− mice compared with WT mice, suggesting that IL-27 is dispensable for immunity but mediates redundant immune and bone cell functions during infection. In vitro studies and bulk RNA-seq of infected tibiae showed that IL-27 increased nos1, nos2, il17a, il17f, and rorc expression but did not directly stimulate chemotaxis. Collectively, these results identify a novel phenomenon of IL-27 expression by osteoblasts immediately following S. aureus infection of bone and suggest a protective role of systemic IL-27 in osteomyelitis.

References

[1] Schwarz EM et al. 2018 International Consensus Meeting on musculoskeletal infection: research priorities from the general assembly questions. J. Orthop. Res., 2019, 37: 997-1006

[2] Tande AJ, Patel R. Prosthetic joint infection. Clin. Microbiol Rev., 2014, 27: 302-345

[3] Stulberg JJ et al. Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA, 2010, 303: 2479-2485

[4] Masters, E. A. et al. Skeletal infections: microbial pathogenesis, immunity and clinical management. Nat. Rev. Microbiol. 20, 385–400 (2022). https://doi.org/10.1038/s41579-022-00686-0.

[5] Kates SL, Tornetta P 3rd. Commentary on secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition originally published in the Journal of Bone and Mineral Research. J. Orthop. Trauma, 2020, 34: 221

[6] Goodson KM et al. Streamlining hospital treatment of prosthetic joint infection. J. Arthroplast., 2020, 35: S63-S68

[7] Depypere M et al. Pathogenesis and management of fracture-related infection. Clin. Microbiol Infect., 2020, 26: 572-578

[8] Govaert GAM et al. Diagnosing fracture-related infection: current concepts and recommendations. J. Orthop. Trauma, 2020, 34: 8-17

[9] Kandel CE et al. Predictors of treatment failure for hip and knee prosthetic joint infections in the setting of 1- and 2-stage exchange arthroplasty: a multicenter retrospective cohort. Open Forum Infect. Dis., 2019, 6: ofz452

[10] Masters EA et al. Evolving concepts in bone infection: redefining “biofilm”, “acute vs. chronic osteomyelitis”, “the immune proteome” and “local antibiotic therapy”. Bone Res., 2019, 7: 20

[11] Kaplan SL. Recent lessons for the management of bone and joint infections. J. Infect., 2014, 68: S51-S56

[12] Assis LM, Nedeljkovic M, Dessen A. New strategies for targeting and treatment of multi-drug resistant Staphylococcus aureus. Drug Resist. Updat., 2017, 31: 1-14

[13] Weigelt JA et al. Surgical site infections: causative pathogens and associated outcomes. Am. J. Infect. Control, 2010, 38: 112-120

[14] van Hal SJ et al. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin. Microbiol. Rev., 2012, 25: 362-386

[15] Wong HR, Lindsell CJ, Lahni P, Hart KW, Gibot S. Interleukin 27 as a sepsis diagnostic biomarker in critically ill adults. Shock, 2013, 40: 382-386

[16] Wong HR, Liu KD, Kangelaris KN, Lahni P, Calfee CS. Performance of interleukin-27 as a sepsis diagnostic biomarker in critically ill adults. J. Crit. Care, 2014, 29: 718-722

[17] Hanna WJ, Berrens Z, Langner T, Lahni P, Wong HR. Interleukin-27: a novel biomarker in predicting bacterial infection among the critically ill. Crit. Care, 2015, 19

[18] He Y et al. Multiplex cytokine profiling identifies interleukin-27 as a novel biomarker for neonatal early onset sepsis. Shock, 2017, 47: 140-147

[19] Jacobs L et al. Interleukin-27 as a candidate diagnostic biomarker for bacterial infection in immunocompromised pediatric patients. PLoS One, 2018, 13: e0207620

[20] Wong HR CN et al. Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit. Care, 2012, 16

[21] Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev. Immunol., 2015, 33: 417-443

[22] Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol., 2005, 5: 521-531

[23] Morita Y, Masters EA, Schwarz EM, Muthukrishnan G. Interleukin-27 and its diverse effects on bacterial infections. Front. Immunol., 2021, 12: 678515

[24] Diveu C et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol., 2009, 182: 5748-5756

[25] Hall AO et al. The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-induced pathology. Immunity, 2012, 37: 511-523

[26] Cao J et al. IL-27 controls sepsis-induced impairment of lung antibacterial host defence. Thorax, 2014, 69: 926-937

[27] Robinson KM et al. The role of IL-27 in susceptibility to post-influenza Staphylococcus aureus pneumonia. Respir. Res., 2015, 16: 10

[28] Seita J et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood, 2008, 111: 1903-1912

[29] Pflanz S et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol., 2004, 172: 2225-2231

[30] Guzzo C, Che Mat NF, Gee K. Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes. J. Biol. Chem., 2010, 285: 24404-24411

[31] Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA, 2003, 100: 15047-15052

[32] Nishitani K et al. Quantifying the natural history of biofilm formation in vivo during the establishment of chronic implant-associated Staphylococcus aureus osteomyelitis in mice to identify critical pathogen and host factors. J. Orthop. Res., 2015, 33: 1311-1319

[33] Masters EA et al. Identification of Penicillin Binding Protein 4 (PBP4) as a critical factor for Staphylococcus aureus bone invasion during osteomyelitis in mice. PLoS Pathog., 2020, 16: e1008988

[34] Nishitani, K. et al. IsdB antibody-mediated sepsis following S. aureus surgical site infection. JCI Insight 5, e141164 (2020).

[35] Masters EA et al. Distinct vasculotropic versus osteotropic features of S. agalactiae versus S. aureus implant-associated bone infection in mice. J. Orthop. Res., 2021, 39: 389-401

[36] Varrone JJ et al. Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters. J. Orthop. Res., 2014, 32: 1389-1396

[37] Frangieh M et al. IL-27: an endogenous constitutive repressor of human monocytes. Clin. Immunol., 2020, 217: 108498

[38] Ivanov II et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper. Cells Cell, 2006, 126: 1121-1133

[39] Fan J et al. IL-27 is elevated in sepsis with acute hepatic injury and promotes hepatic damage and inflammation in the CLP model. Cytokine, 2020, 127: 154936

[40] Ellington JK et al. Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. J. Bone Jt. Surg. Br., 2003, 85: 918-921

[41] Ellington JK et al. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J. Orthop. Res., 2006, 24: 87-93

[42] Walter, N., Mendelsohn, D., Brochhausen, C., Rupp, M. & Alt, V. Intracellular S. aureus in osteoblasts in a clinical sample from a patient with chronic osteomyelitis-a case report. Pathogens 10, 1064 (2021).

[43] Ellington JK, Elhofy A, Bost KL, Hudson MC. Involvement of mitogen-activated protein kinase pathways in Staphylococcus aureus invasion of normal osteoblasts. Infect. Immun., 2001, 69: 5235-5242

[44] Reott MA Jr, Ritchie-Miller SL, Anguita J, Hudson MC. TRAIL expression is induced in both osteoblasts containing intracellular Staphylococcus aureus and uninfected osteoblasts in infected cultures. FEMS Microbiol. Lett., 2008, 278: 185-192

[45] Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol, 2009, 17: 59-65

[46] Claro T et al. Staphylococcus aureus protein A binding to osteoblast tumour necrosis factor receptor 1 results in activation of nuclear factor kappa B and release of interleukin-6 in bone infection. Microbiology, 2013, 159: 147-154

[47] Claro T et al. Staphylococcus aureus protein A binds to osteoblasts and triggers signals that weaken bone in osteomyelitis. PLoS One, 2011, 6: e18748

[48] Ning RD, Zhang XL, Li QT, Guo XK. The effect of Staphylococcus aureus on apoptosis of cultured human osteoblasts. Orthop. Surg., 2011, 3: 199-204

[49] Mohamed W et al. Intracellular proliferation of S. aureus in osteoblasts and effects of rifampicin and gentamicin on S. aureus intracellular proliferation and survival. Eur. Cell Mater., 2014, 28: 258-268

[50] Valour, F. et al. Antimicrobial activity against intra-osteoblastic Staphylococcus aureus. Antimicrob. Agents Chemother. 59, 2029–36 (2015).

[51] Krauss, J. L. et al. Staphylococcus aureus infects osteoclasts and replicates intracellularly. mBio 10, e02447–19 (2019).

[52] Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J. Immunol., 2003, 170: 2106-2112

[53] Lin, Y. et al. mRNA transcriptome analysis of bone in a mouse model of implant-associated Staphylococcus aureus osteomyelitis. Infect. Immun. 89, e00814–20 (2021).

[54] Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum., 2010, 62: 402-413

[55] Furukawa M et al. IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. J. Immunol., 2009, 183: 2397-2406

[56] Kamiya S et al. Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J. Bone Min. Metab., 2007, 25: 277-285

[57] Shukla P et al. Interleukin 27 (IL-27) alleviates bone loss in estrogen-deficient conditions by induction of early growth response-2 gene. J. Biol. Chem., 2017, 292: 4686-4699

[58] Li X LW et al. Interleukin-27 prevents LPS-induced inflammatory osteolysis by inhibiting osteoclast formation and function. Am. J. Transl. Res., 2019, 11: 1154-1169

[59] Terkawi MA et al. Identification of IL-27 as potent regulator of inflammatory osteolysis associated with vitamin E-blended ultra-high molecular weight polyethylene debris of orthopedic implants. Acta Biomater., 2019, 89: 242-251

[60] Niedbala W et al. Interleukin 27 attenuates collagen-induced arthritis. Ann. Rheum. Dis., 2008, 67: 1474-1479

[61] Pickens SR et al. Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum., 2011, 63: 2289-2298

[62] Muthukrishnan, G., Masters, E. A., Daiss, J. L. & Schwarz, E. M. Mechanisms of immune evasion and bone tissue colonization that make staphylococcus aureus the primary pathogen in osteomyelitis. Curr. Osteoporos. Rep. 17, 395–404 (2019).

[63] Wang L, Cao J, Li C, Zhang L. IL-27/IL-27 receptor signaling provides protection in clostridium difficile-induced colitis. J. Infect. Dis., 2018, 217: 198-207

[64] Gao F et al. Interleukin-27 is elevated in sepsis-induced myocardial dysfunction and mediates inflammation. Cytokine, 2016, 88: 1-11

[65] Zhu X et al. Systemic delivery of IL-27 by an adeno-associated viral vector inhibits T cell-mediated colitis and induces multiple inhibitory pathways in T cells. J. Leukoc. Biol., 2016, 100: 403-411

[66] Stumhofer JS et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat. Immunol., 2010, 11: 1119-1126

[67] Pflanz S et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity, 2002, 16: 779-790

[68] Shimozato O et al. The secreted form of p28 subunit of interleukin (IL)−27 inhibits biological functions of IL-27 and suppresses anti-allogeneic immune responses. Immunology, 2009, 128: e816-e825

[69] Muthukrishnan, G. et al. Humanized mice exhibit exacerbated abscess formation and osteolysis during the establishment of implant-associated staphylococcus aureus osteomyelitis. Front. Immunol. 12, 651515 (2021).

[70] Morgenstern, M. et al. The AO trauma CPP bone infection registry: epidemiology and outcomes of Staphylococcus aureus bone infection. J. Orthop. Res. 39, 136–146 (2020).

[71] Lu SC, Wu HW, Lin YJ, Chang SF. The essential role of Oct-2 in LPS-induced expression of iNOS in RAW 264.7 macrophages and its regulation by trichostatin A. Am. J. Physiol. Cell Physiol., 2009, 296: C1133-C1139

[72] Fang FC, Vazquez-Torres A. Reactive nitrogen species in host-bacterial interactions. Curr. Opin. Immunol., 2019, 60: 96-102

[73] Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics, 2018, 34: i884-i890

[74] Dobin A et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 2013, 29: 15-21

[75] Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res., 2013, 41: e108

[76] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 2014, 15

Funding

U.S. Department of Health & Human Services | National Institutes of Health (NIH)(AR069655)

U.S. Department of Health & Human Services | National Institutes of Health (NIH)

NIH NIAMS P30 AR069655 pilot grant

U.S. Department of Health & Human Services | National Institutes of Health (NIH)

AO Trauma Clinical Priority Program

U.S. Department of Health & Human Services | National Institutes of Health (NIH)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(AR072000)